Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer
CTR20171624Phase 3Active
- Sponsor
- Pfizer
- Start
- Jun 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lorlatinib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jun 2018; status: active.
02
Drugs
lorlatinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171624.